Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

575 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical Practice.
Tateishi A, Okuma Y, Goto Y, Arakaki M, Igawa YS, Torasawa M, Shinno Y, Yoshida T, Horinouchi H, Yamamoto N, Ohe Y. Tateishi A, et al. Among authors: okuma y. Anticancer Res. 2024 Dec;44(12):5501-5513. doi: 10.21873/anticanres.17376. Anticancer Res. 2024. PMID: 39626947
Real-world Data on the Incidence of Coronavirus Disease (COVID-19) in Patients With Advanced Thoracic Cancer During the Early Phase of the Pandemic in Japan.
Fukuda A, Yoshida T, Yagishita S, Shiotsuka M, Kobayashi O, Iwata S, Umeguchi H, Yanagida M, Irino Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Yamamoto N, Ohe Y. Fukuda A, et al. Among authors: okuma y. Anticancer Res. 2023 Feb;43(2):919-926. doi: 10.21873/anticanres.16235. Anticancer Res. 2023. PMID: 36697081
Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
Tamura K, Okuma Y, Nomura S, Fukuda A, Masuda K, Matsumoto Y, Shinno Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Ohe Y. Tamura K, et al. Among authors: okuma y. J Cancer Res Clin Oncol. 2024 Apr 26;150(4):216. doi: 10.1007/s00432-024-05649-x. J Cancer Res Clin Oncol. 2024. PMID: 38668936 Free PMC article.
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma.
Okuma Y, Goto Y, Ohyanagi F, Sunami K, Nakahara Y, Kitazono S, Kudo K, Tambo Y, Kanda S, Yanagitani N, Horiike A, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Nishio M, Ohe Y, Hosomi Y. Okuma Y, et al. Cancer Med. 2020 Oct;9(20):7418-7427. doi: 10.1002/cam4.3385. Epub 2020 Aug 19. Cancer Med. 2020. PMID: 32813912 Free PMC article. Clinical Trial.
Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Shirasawa M, Yoshida T, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: okuma y. Eur J Cancer. 2020 Nov;140:28-36. doi: 10.1016/j.ejca.2020.08.028. Epub 2020 Oct 8. Eur J Cancer. 2020. PMID: 33039811
Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment.
Shirasawa M, Yoshida T, Horinouchi H, Kitano S, Arakawa S, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Kanda S, Watanabe R, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: okuma y. Br J Cancer. 2021 Mar;124(5):925-932. doi: 10.1038/s41416-020-01188-7. Epub 2020 Nov 30. Br J Cancer. 2021. PMID: 33250511 Free PMC article.
575 results